A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
Public ClinicalTrials.gov record NCT03809611. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3-month, Randomized, Placebo-controlled, Double-masked, Multi-center Study to Evaluate the Safety and Efficacy of Topical Ocular UNR844-Cl in Subjects With Presbyopia
Study identification
- NCT ID
- NCT03809611
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Interventions
- UNR844-Cl Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 45 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2019
- Primary completion
- Dec 15, 2019
- Completion
- Dec 15, 2019
- Last update posted
- May 10, 2022
2019
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Mission Hills | California | 91345 | — |
| Novartis Investigative Site | Newport Beach | California | 92663 | — |
| Novartis Investigative Site | Largo | Florida | 33773 | — |
| Novartis Investigative Site | Mt. Dora | Florida | 32757 | — |
| Novartis Investigative Site | Washington | Missouri | 63090 | — |
| Novartis Investigative Site | Allenwood | Pennsylvania | 17810 | — |
| Novartis Investigative Site | Cranberry Township | Pennsylvania | 16066 | — |
| Novartis Investigative Site | Kingston | Pennsylvania | 18704 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38119 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37205-2013 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37205 | — |
| Novartis Investigative Site | Cedar Park | Texas | 78613 | — |
| Novartis Investigative Site | Houston | Texas | 77204 | — |
| Novartis Investigative Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03809611, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 10, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03809611 live on ClinicalTrials.gov.